Summit posts Q2 earnings, advances ivonescimab pivotal trials
Summit reported Q2 financial results and announced updated survival data from Phase III ivonescimab studies, demonstrating significant clinical benefits across multiple NSCLC indications.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed